Description
JS105 is an experimental medication currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being investigated as a potential treatment option, often in combination with other anti-cancer therapies like capecitabine, fluzoparib, fulvestrant, or toripalimab. The trials are in the early phase (Phase 1), primarily focused on determining the safe dosage and how the drug is processed by the body (pharmacokinetics). Researchers are also looking for early signs that the drug might be effective (preliminary efficacy). These trials are open-label, meaning both the researchers and the patients know which treatment is being given. The trials are enrolling patients with advanced solid tumors, and specific trials for JS105 in colorectal cancer are including patients with certain HER2 mutations or expression levels, and PIK3CA mutations.
Mechanism of Action
JS105 is being studied as an anti-tumor therapy. The specific way it works (its mechanism of action) is currently being investigated in clinical trials. It is being tested in combination with other established anti-cancer drugs to see if it can enhance their effects or offer a new approach to treating advanced solid tumors.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.